Henry Ford Health System – Rheumatology
Primary Coordinator: Jenna Hudy 313-916-9328
- Indication: Systemic Lupus Erythematosus
- Enrollment Status: Open
- Protocol: CVAY736F12301
- Drug: Ianalumab
- Sponsor: Novartis
- Description: A randomized, double-blind, parallel group, placebo-controlled multicenter phase 3 study to evaluate efficacy, safety and tolerability of two regimens of ianalumab on top of standard-of-care therapy in patients with systemic lupus erythematosus (SIRIUS-SLE 1)